Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy
Carlo Fumagalli, Francesco Cappelli, Mathew S. Maurer, Fabian aus dem Siepen, Angela Dispenzieri, Pablo Garcia-Pavia, Mazen Hanna, Martin Carlsson, Thibaud Damy · 2026
Read Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy by Carlo Fumagalli, Francesco Cappelli, Mathew S. Maurer, Fabian aus dem Siepen, Angela Dispenzieri, Pablo Garcia-Pavia, Mazen Hanna, Martin Carlsson, Thibaud Damy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13691042.txt.
Description
Carlo Fumagalli and co-authors study a heart drug in older patients in a 2026 analysis. The drug, tafamidis, treats a disease in which a blood protein builds up in the heart wall and stiffens it. The drug improves outcomes, yet the oldest patients often go untreated. The team pooled data from an early access program and a long running registry to compare results by age group.
Nearly two thousand patients were split into three bands: under eighty, eighty to eighty five, and over eighty five. The oldest group started with worse kidney function and more severe symptoms. Their survival rates at set time points were lower, and hospital visits for heart causes were more frequent each year. Death risk was higher for the oldest group than the youngest, even after adjustments. The authors say starting traits shape outcomes and should guide care plans.
Catalog record
| CREATOR | Carlo Fumagalli, Francesco Cappelli, Mathew S. Maurer, Fabian aus dem Siepen, Angela Dispenzieri, Pablo Garcia-Pavia, Mazen Hanna, Martin Carlsson, Thibaud Damy |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |